ProCE Banner Activity

My Experiences Managing Immune-Related Hepatic and Neurologic Adverse Events in Patients Receiving Checkpoint Inhibitor Therapy

Clinical Thought
This commentary describes 2 cases from my clinic and our experience managing hepatic, neurologic, and hematologic adverse events in patients treated for melanoma with immune checkpoint inhibitors.

Released: October 27, 2016

Expiration: October 26, 2017

No longer available for credit.

Share

Faculty

Michael Postow

Michael Postow, MD

Chief, Melanoma Service
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Michael Postow, MD

Chief, Melanoma Service
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Michael Postow, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb and funds for research support from Array BioPharma, Bristol-Myers Squibb, and Novartis.